UK Grants Marketing Authorization for Novartis’ Radioligand Therapy for Advanced Prostate Cancer August 16, 2022 AutoBot News 0 The UK’s MHRA has granted marketing authorization for Novartis’ radioligand therapy, Pluvicto, for the treatment of advanced prostate cancer in Great Britain.